In a report published Sunday, Goldman Sachs analyst David H. Roman upgraded the rating on Abbott Laboratories (NYSE: ABT) from Neutral to Buy and raised the price target on the company from $38.00 to $44.00.In the report, Goldman Sachs noted, "(1) Emerging ...
[Published Benzinga.com - May 20 2013]